DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for inherited aplastic anemia — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleInherited aplastic anemia maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for inherited aplastic anemia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
DNA polymerase alpha 1, catalytic subunit (POLA1) — POLA1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet atpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8QJ7 · 3.07 Å · ligand ADENOSINE-5'-TRIPHOSPHATE (ATP). Experimental structure, not a prediction.
What the evidence adds up to
A 2009 retrospective study of 42 children with moderate aplastic anaemia compared 18 patients who received antithymocyte globulin, cyclosporin A, and androgen with 24 patients who received cyclosporin A and androgen alone. The response rate in the ATG group was 83.33% versus 41.7% in the non-ATG group, and transfusion-independent survival was also 83.33% versus 50%. Fewer patients in the ATG group progressed to severe aplastic anaemia. The authors concluded that immunosuppressive therapy including ATG benefits children with moderate aplastic anaemia.
A 2016 review notes that aplastic anaemia is a serious haematological malignant disease in children, that severe AA is difficult to treat and may lead to high mortality, and that acquired AA accounts for 95% of all cases. The review summarises recent progress in understanding the pathogenesis of acquired AA in children, focusing on cellular immunity and gene factors. It does not report any new treatment data.
A 1985 article states that inherited aplastic anaemias carry a grim prognosis and describes the focus on definitive treatment of highly lethal anaemias. No specific results or numbers are given.
What is still missing is prospective randomised trial data for ATG in moderate aplastic anaemia in children, as the 2009 study is retrospective and small. The pathogenesis review does not translate into a validated treatment target. No trial has yet stratified inherited aplastic anaemia patients by genetic subtype to test targeted therapy, and funding for such trials remains scarce.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pediatric Hematology and Oncology · 2009 · 13 citations
THE BENEFIT OF ATG IN IMMUNOSUPPRESSIVE THERAPY OF CHILDREN WITH MODERATE APLASTIC ANEMIA
AbstractBACKGROUND: Previous studies specifically focused on the immunosuppressive therapy (IST) of children with moderate aplastic anemia (MAA) are rare. The aim of this study was to evaluate the advantage of using antithymocyte globulin (ATG) in the IST and its outcome of children with MAA. METHODS: Forty-two children diagnosed with moderate aplastic anemia from 1993 to 2006 were retrospectively reviewed. Eighteen patients treated with ATG, cyclosporin A (CSA), and androgen are defined as the ATG group, the other 24 patients treated with CSA and androgen are defined as the non-ATG group. Survival and hematological response of the two groups were studied. RESULTS: Response rate and transfusion-independent survival of the ATG group were both significantly higher than those of the non-ATG group (83.33 vs. 41.7%, p = .006; and 83.33 vs. 50%, p = .043, respectively). Compared with non-ATG group, fewer patients in ATG group progress to severe aplastic anemia (p = .03). CONCLUSION: Immunosuppressive therapy including ATG benefits children with moderate aplastic anemia.
Recent progeress of pathogenesis in acquired aplastic anemia
AbstractAplastic anemia (AA) is a serious disease of hematological malignant disease in children.Severe AA is difficult to treat and may lead to high motality.Acquired AA accounts for 95% of all cases, so it's significant to lucubrate the pathogenesis of acquired AA for clinic diagnosis and therapy.The documents in recent 5 years are collected, and a reviews about the progress of pathogenesis in acquired AA children is provided.
Key words:
Aplastic anemia; Pathogenesis; Cellular immunity; Gene; Child
AbstractAlthough the anemias that are sequelae of exposure to therapeutic irradiation or cytotoxic drugs are usually self-limited, other forms of aplastic anemia—both inherited and acquired—carry a grim prognosis. Nevertheless, the focus is on “definitive treatment” of the highly lethal anemias in this first of a series of articles on progress against blood diseases.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
